Sun Pharmaceutical Industries Limited announced the appointment of Rolf Hoffmann as Independent Director and Aalok Shanghvi as Whole-time Director on the company’s Board. Rolf Hoffmann is a Strategic and results-orientated Executive who is highly respected for expertise in creating and optimizing commercial opportunities in all global markets. He has over 29 years of experience managing…
Pharma major Sun Pharmaceutical Industries Limited announced the acquisition of minority stake in Agatsa Software Private Limited and Remidio Innovative Solutions Private Limited. According to the company’s exchange filing, “This is to inform you that Sun Pharmaceutical Industries Limited (which includes its subsidiaries and/or associate companies) [“Company”], has entered into agreements to acquire minority stake…
Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company, announced the retirement of Kalyanasundaram Subramanian as Whole-time Director of the company, with effect from February 13, 2023. According to the company’s exchange filing, “The term of Mr. Kalyanasundaram Subramanian (DIN: 00179072), Whole-time Director would end on February 13, 2023, and accordingly he shall retire from…
Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or its associated companies, Sun Pharma) and Concert Pharmaceuticals, Inc. (Concert) announced that they have entered into a definitive agreement pursuant to which Sun Pharma will acquire all of the outstanding shares of Concert by way of a tender offer for an initial cash payment of 8.00…
Sun Pharmaceutical Industries Limited announced that its Chairman and member of the Board, Israel Makov, will retire from the company upon the completion of his current term post Sun Pharma’s Annual General Meeting on August 29, 2022, after having led the organisation for 10 years. He was appointed a Board member and the Chairman in…
Sun Pharmaceutical Industries Limited (Sun Pharma), announced that one of its subsidiaries, S.C. Terapia S.A., Romania has acquired the Uractiv portfolio from Fiterman Pharma in Romania. The Uractiv portfolio comprises food supplements including minerals, vitamins and adjuvants; cosmetics and medical devices used for maintaining urinary tract health. Uractiv is the No. 1 brand in its…
Sun Pharmaceuticals Industries Limited announced it has acquired additional 11.28% equity stake in Zenotech Laboratories Limited. Post this acquisition, Sun Pharma would increase its shareholding from 57.56% to 68.84% in the company. According to the company’s exchange filing, “this is to inform you that Suo Pharmaceutical Industries Limited (“Company”) has entered into a share purchase…
Sun Pharmaceutical Industries Ltd. announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for expanding access to Lilly’s drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India, the release said. Baricitinib is used in combination with remdesivir for the treatment of…
Sun Pharmaceutical Industries Ltd, a Mumbai-based generic pharmaceutical company, announced that it has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The Company received approval from the Drugs Controller General of India (DCGI) for conducting Phase II clinical trials in April this year. The clinical trial will…
Sun Pharmaceutical Industries Ltd, a Mumbai-headquartered pharmaceutical company, announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. The company said that Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation…